VRDN Q3 2021 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$2B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$208,000

Gross Profit

-$8M-3804.3% margin

Operating Income

-$14M-6795.2% margin

Net Income

-$14M-6751.4% margin

EPS (Diluted)

$-1.26

QoQ Revenue Growth

-80.9%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$221M

Total Liabilities

$17M

Stockholders' Equity

$205M

Cash & Equivalents

$139M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$208,000	$0	—
Gross Profit	-$8M	$0	—
Operating Income	-$14M	-$5M	-161.3%
Net Income	-$14M	-$5M	-155.6%

Revenue Segments

Collaboration Revenue

$208,000100%